Intrinsic tenase complex (Factor IXa-Factor VIIIa) (FIXa-FVIIIa)

The intrinsic tenase complex is a critical enzymatic assembly in the coagulation cascade, primarily responsible for the amplification of thrombin generation (StatPearls, "Physiology, Coagulation Cascade"). It consists of the activated serine protease Factor IXa and its essential non-enzymatic cofactor, Factor VIIIa, which assemble on procoagulant phospholipid surfaces in the presence of calcium ions (PubMed, PMID: 11007014). This complex catalyzes the conversion of Factor X to Factor Xa, a rate-limiting step in the formation of the prothrombinase complex. Deficiencies in Factor VIII or Factor IX result in Hemophilia A and B, respectively, leading to severe bleeding disorders (NIH, "Hemophilia"). Modern therapeutics target this complex through various modalities: replacement of deficient factors with recombinant proteins, the use of bispecific antibodies like emicizumab that mimic Factor VIIIa function (NEJM, 2017), and the development of novel anticoagulants targeting upstream components like Factor XIa (e.g., milvexian, asundexian) to reduce thrombotic risk with a lower incidence of bleeding compared to traditional anticoagulants (Lancet, 2022). Monitoring of the intrinsic pathway is typically achieved through the activated partial thromboplastin time (aPTT) and specific factor activity assays.

Other names

Intrinsic coagulation complexIntrinsic XaseFactor IXa-Factor VIIIa complexTenase complexIntrinsic pathway

The complex catalyzes the conversion of Factor X to Factor Xa. Therapeutic agents either replace deficient components (Factor VIII or IX), mimic the scaffolding function of the cofactor (emicizumab), or inhibit the enzymatic activity of the complex or its upstream activators (Factor XIa) to prevent thrombosis.